Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Message From the Editor-in-Chief
Message From the Editor-in-Chief
Toshihisa Anzai
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML

2020 Volume 84 Issue 11 Pages 1890-1894

Details

Dear Colleagues,

On behalf of the Circulation Journal , I am pleased to report the most frequently quoted CJ papers in 2019 by category that substantially contributed to the 2019 Impact Factor of the Journal.

The Most Frequently Quoted CJ Papers (2017–2018) in 2019 by Category

The following papers, published in 2017–2018, were among the most frequently quoted papers in 2019 by category, thereby substantially contributing to the 2019 Impact Factor of the Journal (number in the parenthesis denotes the number of quotation in 2017–2018).

1. Arrhythmia/Electrophysiology

1. (25) Yamashita Y, Uozumi R, Hamatani Y, Esato M, Chun YH, Tsuji H, et al. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients: Fushimi AF registry. Circ J 2017; 81: 1278–1285.

2. (15) Heeger CH, Wissner E, Knöll M, Knoop B, Reissmann B, Mathew S, et al. Three-year clinical outcome after 2nd-generation cryoballoon-based pulmonary vein isolation for the treatment of paroxysmal and persistent atrial fibrillation: A 2-center experience. Circ J 2017; 81: 974–980.

3. (12) Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, et al; SAKURA AF registry investigators. Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation: Findings from the SAKURA AF registry. Circ J 2018; 82: 2500–2509.

4. (8) Kokubo Y, Watanabe M, Higashiyama A, Nakao YM, Kusano K, Miyamoto Y. Development of a basic risk score for incident atrial fibrillation in a Japanese general population: The Suita study. Circ J 2017; 81: 1580–1588.

5. (7) Tanaka N, Inoue K, Tanaka K, Toyoshima Y, Oka T, Okada M, et al. Automated ablation annotation algorithm reduces re-conduction of isolated pulmonary vein and improves outcome after catheter ablation for atrial fibrillation. Circ J 2017; 81: 1596–1602.

6. (6) Natsume Y, Oaku K, Takahashi K, Nakamura W, Oono A, Hamada S, et al. Combined analysis of human and experimental murine samples identified novel circulating microRNAs as biomarkers for atrial fibrillation. Circ J 2018; 82: 965–973.

 (6) Yu HT, Yang PS, Kim TH, Uhm JS, Kim JY, Joung B, et al. Poor rhythm outcome of catheter ablation for early-onset atrial fibrillation in women: Mechanistic insight. Circ J 2018; 82: 2259–2268.

8. (5) Kawabata M, Goya M, Sasaki T, Maeda S, Shirai Y, Nishimura T, et al. Left atrial appendage thrombi formation in Japanese non-valvular atrial fibrillation patients during anticoagulation therapy: Warfarin vs. direct oral anticoagulants. Circ J 2017; 81: 645–651.

 (5) Deguchi I, Tanahashi N, Takao M. Timing of treatment initiation with oral anticoagulants for acute ischemic stroke in patients with nonvalvular atrial fibrillation. Circ J 2017; 81: 180–184.

 (5) Hayashi K, Tsuda T, Nomura A, Fujino N, Nohara A, Sakata K, et al; Hokuriku-plus AF registry investigators. Impact of b-type natriuretic peptide level on risk stratification of thromboembolism and death in patients with nonvalvular atrial fibrillation: The Hokuriku-plus AF registry. Circ J 2018; 82: 1271–1278.

2. Cardiovascular Intervention

1. (8) Yazaki K, Otsuka M, Kataoka S, Kahata M, Kumagai A, Inoue K, et al. Applicability of 3-dimensional quantitative coronary angiography-derived computed fractional flow reserve for intermediate coronary stenosis. Circ J 2017; 81: 988–992.

 (8) Lin YN, Chen YH, Wang HJ, Hung JS, Chang KC, Lo PH. Atrial septostomy for left atrial decompression during extracorporeal membrane oxygenation by Inoue balloon catheter. Circ J 2017; 81: 1419–1423.

3. (7) Wada H, Dohi T, Miyauchi K, Doi S, Naito R, Konishi H, et al. Independent and combined effects of serum albumin and C-reactive protein on long-term outcomes of patients undergoing percutaneous coronary intervention. Circ J 2017; 81: 1293–1300.

4. (5) Tanaka N, Nakamura M, Akasaka T, Kadota K, Uemura S, Amano T, et al; CVIT-DEFER registry investigators. One-year outcome of fractional flow reserve-based coronary intervention in Japanese daily practice: CVIT-DEFER registry. Circ J 2017; 81: 1301–1306.

3. Cardiovascular Surgery

1. (7) Gatti G, Perrotti A, Reichart D, Maschietto L, Onorati F, Chocron S, et al. Glycated hemoglobin and risk of sternal wound infection after isolated coronary surgery. Circ J 2017; 81: 36–43.

 (7) Ji Q, Shi Y, Xia L, Ma R, Shen J, Lai H, et al. Revascularization of left coronary system using a skeletonized left internal mammary artery: Sequential vs. separate grafting. Circ J 2018; 82: 102–109.

3. (6) Chou AH, Chen TH, Chen CY, Chen SW, Lee CW, Liao CH, et al. Long-term outcome of cardiac surgery in 1,040 liver cirrhosis patient: Nationwide population-based cohort study. Circ J 2017; 81: 476–484.

4. Heart Failure

1. (10) Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, et al; Kanagawa aquaresis investigators. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment: Results from the K-STAR study. Circ J 2018; 82: 159–167.

2. (9) Minamisawa M, Miura T, Motoki H, Ueki Y, Nishimura H, Shimizu K, et al. Geriatric nutritional risk index predicts cardiovascular events in patients at risk for heart failure. Circ J 2018; 82: 1614–1622.

3. (8) Hatazawa K, Tanaka H, Nonaka A, Takada H, Soga F, Hatani Y, et al. Baseline global longitudinal strain as a predictor of left ventricular dysfunction and hospitalization for heart failure of patients with malignant lymphoma after anthracycline therapy. Circ J 2018; 82: 2566–2574.

4. (7) Harada E, Mizuno Y, Kugimiya F, Shono M, Maeda H, Yano N, et al. B-type natriuretic peptide in heart failure with preserved ejection fraction: Relevance to age-related left ventricular modeling in Japanese. Circ J 2017; 81: 1006–1013.

5. (6) De Rosa R, Silverio A, Baldi C, Di Maio M, Prota C, Radano I, et al. Transcatheter repair of functional mitral regurgitation in heart failure patients: A meta-analysis of 23 studies on MitraClip implantation. Circ J 2018; 82: 2800–2810.

 (6) Mebazaa A, Seronde MF, Gayat E, Tibazarwa K, Anumba DOC, Akrout N, et al. Imbalanced angiogenesis in peripartum cardiomyopathy: Diagnostic value of placenta growth factor. Circ J 2017; 81: 1654–1661.

 (6) Yoshioka D, Sakaniwa R, Toda K, Samura T, Saito S, Kashiyama N, et al. Relationship between bacteremia and hemorrhagic stroke in patients with continuous-flow left ventricular assist device. Circ J 2018; 82: 448–456.

8. (5) Oda S, Utsunomiya D, Nakaura T, Yuki H, Kidoh M, Morita K, et al. Identification and assessment of cardiac amyloidosis by myocardial strain analysis of cardiac magnetic resonance imaging. Circ J 2017; 81: 1014–1021.

 (5) Kuragaichi T, Kurozumi Y, Ohishi S, Sugano Y, Sakashita A, Kotooka N, et al. Nationwide survey of palliative care for patients with heart failure in Japan. Circ J 2018; 82: 1336–1343.

 (5) Katsimichas T, Ohtani T, Motooka D, Tsukamoto Y, Kioka H, Nakamoto K, et al. Non-ischemic heart failure with reduced ejection fraction is associated with altered intestinal microbiota. Circ J 2018; 82: 1640–1650.

5. Imaging

1. (7) Motoyama S, Ito H, Sarai M, Nagahara Y, Miyajima K, Matsumoto R, et al. Ultra-high-resolution computed tomography angiography for assessment of coronary artery stenosis. Circ J 2018; 82: 1844–1851.

2. (5) Michikura M, Ogura M, Yamamoto M, Sekimoto M, Fuke C, Hori M, et al. Achilles tendon ultrasonography for diagnosis of familial hypercholesterolemia among Japanese subjects. Circ J 2017; 81: 1879–1885.

6. Ischemic Heart Disease

1. (10) De Rosa R, Vasa-Nicotera M, Leistner DM, Reis SM, Thome CE, Boeckel JN, et al. Coronary atherosclerotic plaque characteristics and cardiovascular risk factors: Insights from an optical coherence tomography study. Circ J 2017; 81: 1165–1173.

 (10) Lee CH, Cheng CL, Kao Yang YH, Chao TH, Chen JY, Li YH. Cardiovascular and bleeding risks in acute myocardial infarction newly treated with ticagrelor vs. clopidogrel in Taiwan. Circ J 2018; 82: 747–756.

3. (8) Fujisue K, Sugamura K, Kurokawa H, Matsubara J, Ishii M, Izumiya Y, et al. Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction. Circ J 2017; 81: 1174–1182.

4. (7) Emori H, Kubo T, Kameyama T, Ino Y, Matsuo Y, Kitabata H, et al. Diagnostic accuracy of quantitative flow ratio for assessing myocardial ischemia in prior myocardial infarction. Circ J 2018; 82: 807–814.

5. (6) Kang SH, Choi EK, Han KD, Lee SR, Lim WH, Cha MJ, et al. Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants: Korean nationwide population-based study. Circ J 2017; 81: 1158–1164.

 (6) Mizuno Y, Hokimoto S, Harada E, Kinoshita K, Yoshimura M, Yasue H. Variant aldehyde dehydrogenase 2 (ALDH2*2) in east asians interactively exacerbates Tobacco smoking risk for coronary spasm: Possible role of reactive aldehydes. Circ J 2017; 81: 96–102.

 (6) Kubo T, Takahata M, Terada K, Mori K, Arita Y, Ino Y, et al. Retrospective comparison of long-term clinical outcomes between percutaneous coronary intervention and medical therapy in stable coronary artery disease with gray zone fractional flow reserve: COMFORTABLE retrospective study. Circ J 2018; 82: 3044–3051.

 (6) Ozaki Y, Imanishi T, Hosokawa S, Nishiguchi T, Taruya A, Tanimoto T, et al. Association of toll-like receptor 4 on human monocyte subsets and vulnerability characteristics of coronary plaque as assessed by 64-slice multidetector computed tomography. Circ J 2017; 81: 837–845.

7. Molecular Cardiology/Myocardial Disease

1. (4) Zhang M, Zhao GJ, Yin K, Xia XD, Gong D, Zhao ZW, et al. Apolipoprotein A-1 binding protein inhibits inflammatory signaling pathways by binding to apolipoprotein A-1 in THP-1 macrophages. Circ J 2018; 82: 1396–1404. (Molecular Cardiology)

8. Pediatric Cardiology and Adult Congenital Heart Disease

1. (7) Kuwabara M, Niwa K, Toyoda T, Shirai T, Tateno S, Ohuchi H, et al; Research committee of the Japanese society of pediatric cardiology and cardiac surgery. Liver cirrhosis and/or hepatocellular carcinoma occurring late after the fontan procedure: A nationwide survey in Japan. Circ J 2018; 82: 1155–1160.

2. (4) Yamada M, Takahashi K, Kobayashi M, Yazaki K, Takayasu H, Akimoto K, et al. Mechanisms of left ventricular dysfunction assessed by layer-specific strain analysis in patients with repaired tetralogy of fallot. Circ J 2017; 81: 846–854.

 (4) Lee SH, Kim SJ, Kim HJ, Son JS, Lee R, Yoon TG. Acute kidney injury following cardiopulmonary bypass in children: Risk factors and outcomes. Circ J 2017; 81: 1522–1527.

 (4) Ishizaki U, Nagao M, Shiina Y, Fukushima K, Takahashi T, Shimomiya Y, et al. Prediction of fontan-associated liver disease using a novel cine magnetic resonance imaging “vortex flow map” in the right atrium. Circ J 2018; 82: 2143–2151.

9. Peripheral Vascular Disease/Pulmonary Circulation

1. (9) Darocha S, Pietura R, Pietrasik A, Norwa J, Dobosiewicz A, Piłka M, et al. Improvement in quality of life and hemodynamics in chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty. Circ J 2017; 81: 552–557. (Pulmonary Circulation)

 (9) Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M. Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease. Circ J 2018; 82: 546–554. (Pulmonary Circulation)

3. (7) Yokoyama M, Watanabe T, Otaki Y, Watanabe K, Toshima T, Sugai T, et al. Impact of objective malnutrition status on the clinical outcomes in patients with peripheral artery disease following endovascular therapy. Circ J 2018; 82: 847–856. (Peripheral Vascular Disease)

 (7) Kodama A, Koyama A, Sugimoto M, Niimi K, Banno H, Komori K. Association between preoperative frailty and mortality in patients with critical limb ischemia following infrainguinal bypass surgery: Usefulness of the barthel index. Circ J 2018; 82: 267–274. (Peripheral Vascular Disease)

5. (5) Tamura Y, Kumamaru H, Satoh T, Miyata H, Ogawa A, Tanabe N, et al; Japan PH registry (JAPHR) network. Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension. Circ J 2018; 82: 275–282. (Pulmonary Circulation)

 (5) Kondo K, Yanishi K, Hayashida R, Shintani S, Shibata R, Murotani K, et al; TACT follow-up study investigators. Long-term clinical outcomes survey of bone marrow-derived cell therapy in critical limb ischemia in Japan. Circ J 2018; 82: 1168–1178. (Peripheral Vascular Disease)

 (5) Sarashina T, Nakamura K, Akagi S, Oto T, Oe H, Ejiri K, et al. Reverse right ventricular remodeling after lung transplantation in patients with pulmonary arterial hypertension under combination therapy of targeted medical drugs. Circ J 2017; 81: 383–390. (Pulmonary Circulation)

10. Reviews/Editorials

1. (20) Hamburg NM, Creager MA. Pathophysiology of intermittent claudication in peripheral artery disease. Circ J 2017; 81: 281–289. (Review)

2. (14) Lau WB, Ohashi K, Wang Y, Ogawa H, Murohara T, Ma XL, et al. Role of adipokines in cardiovascular disease. Circ J 2017; 81: 920–928. (Review)

3. (9) Chen C, Wei J, AlBadri A, Zarrini P, Bairey Merz CN. Coronary microvascular dysfunction: Epidemiology, pathogenesis, prognosis, diagnosis, risk factors and therapy. Circ J 2017; 81: 3–11. (Review)

 (9) Ferrari R, Balla C, Malagù M, Guardigli G, Morciano G, Bertini M, et al. Reperfusion damage: A story of success, failure, and hope. Circ J 2017; 81: 131–141. (Review)

 (9) Curcio A, Santarpia G, Indolfi C. The Brugada syndrome: From gene to therapy. Circ J 2017; 81: 290–297. (Review)

6. (7) Lei Y, Hu L, Yang G, Piao L, Jin M, Cheng X. Dipeptidyl peptidase-IV inhibition for the treatment of cardiovascular disease: Recent insights focusing on angiogenesis and neovascularization. Circ J 2017; 81: 770–776. (Review)

 (7) Anzai T. Inflammatory mechanisms of cardiovascular remodeling. Circ J 2018; 82: 629–635. (Review)

8. (6) Ishibashi-Ueda H, Matsuyama TA, Ohta-Ogo K, Ikeda Y. Significance and value of endomyocardial biopsy based on our own experience. Circ J 2017; 81: 417–426. (Review)

9. (5) Ikegami R, Shimizu I, Yoshida Y, Minamino T. Metabolomic analysis in heart failure. Circ J 2018; 82: 10–16. (Review)

 (5) Ichiki T, Burnett JC Jr. Atrial natriuretic peptide: Old but new therapeutic in cardiovascular diseases. Circ J 2017; 81: 913–919. (Review)

 (5) Akhirome E, Walton NA, Nogee JM, Jay PY. The complex genetic basis of congenital heart defects. Circ J 2017; 81: 629–634. (Review)

 (5) Ogawa A, Matsubara H. After the dawn: Balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension. Circ J 2018; 82: 1222–1230. (Review)

 (5) Yamamoto K, Ando J. Emerging role of plasma membranes in vascular endothelial mechanosensing. Circ J 2018; 82: 2691–2698. (Review)

11. LBCT/LBCS/Rapid

1. (16) Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al; COMMAND VTE registry investigators. Anticoagulation therapy for venous thromboembolism in the real world: From the COMMAND VTE registry. Circ J 2018; 82: 1262–1270. (LBCS)

2. (14) Nagai T, Yoshikawa T, Saito Y, Takeishi Y, Yamamoto K, Ogawa H, et al; JASPER investigators. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction: A report from the Japanese heart failure syndrome with preserved ejection fraction (JASPER) registry. Circ J 2018; 82: 1534–1545. (LBCS)

3. (12) Kario K, Tomitani N, Kanegae H, Ishii H, Uchiyama K, Yamagiwa K, et al. Comparative effects of an angiotensin II receptor blocker (ARB)/diuretic vs. ARB/calcium-channel blocker combination on uncontrolled nocturnal hypertension evaluated by information and communication technology-based nocturnal home blood pressure monitoring: The NOCTURNE study. Circ J 2017; 81: 948–957. (LBCT)

4. (7) Katsumata Y, Sano F, Abe T, Tamura T, Fujisawa T, Shiraishi Y, et al. The effects of hydrogen gas inhalation on adverse left ventricular remodeling after percutaneous coronary intervention for ST-elevated myocardial infarction: First pilot study in humans. Circ J 2017; 81: 940–947. (LBCT)

12. Other Categories

1. (22) Kaku K, Lee J, Mattheus M, Kaspers S, George J, Woerle HJ; EMPA-REG OUTCOME® investigators. Empagliflozin and cardiovascular outcomes in asian patients with type 2 diabetes and established cardiovascular disease: Results from EMPA-REG OUTCOME®. Circ J 2017; 81: 227–234. (Preventive Medicine)

2. (11) Fukushima N, Ono M, Saiki Y, Sawa Y, Nunoda S, Isobe M. Registry report on heart transplantation in Japan (June 2016). Circ J 2017; 81: 298–303. (Report of Heart Transplantation in Japan)

 (11) Ichibori Y, Mizote I, Maeda K, Onishi T, Ohtani T, Yamaguchi O, et al. Clinical outcomes and bioprosthetic valve function after transcatheter aortic valve implantation under dual antiplatelet therapy vs. aspirin alone. Circ J 2017; 81: 397–404. (Valvular Heart Disease)

4. (10) Pignon B, Sevestre MA, Kanagaratnam L, Pernod G, Stephan D, Emmerich J, et al. Autologous bone marrow mononuclear cell implantation and its impact on the outcome of patients with critical limb ischemia: Results of a randomized, double-blind, placebo-controlled trial. Circ J 2017; 81: 1713–1720. (Regenerative Medicine)

5. (9) Furuhashi M, Yuda S, Muranaka A, Kawamukai M, Matsumoto M, Tanaka M, et al. Circulating fatty acid-binding protein 4 concentration predicts the progression of carotid atherosclerosis in a general population without medication. Circ J 2018; 82: 1121–1129. (Metabolic Disorder)

6. (8) Yoshimura S, Koga M, Sato S, Todo K, Yamagami H, Kumamoto M, et al; SAMURAI study investigators. Two-year outcomes of anticoagulation for acute ischemic stroke with nonvalvular atrial fibrillation: SAMURAI-NVAF study. Circ J 2018; 82: 1935–1942. (Stroke)

7. (7) Takashima N, Arima H, Kita Y, Fujii T, Miyamatsu N, Komori M, et al. Incidence, management and short-term outcome of stroke in a general population of 1.4 million Japanese: Shiga stroke registry. Circ J 2017; 81: 1636–1646. (Epidemiology)

 (7) Furuhashi M, Matsumoto M, Tanaka M, Moniwa N, Murase T, Nakamura T, et al. Plasma xanthine oxidoreductase activity as a novel biomarker of metabolic disorders in a general population. Circ J 2018; 82: 1892–1899. (Metabolic Disorder)

 (7) Liotta F, Annunziato F, Castellani S, Boddi M, Alterini B, Castellini G, et al. Therapeutic efficacy of autologous non-mobilized enriched circulating endothelial progenitors in patients with critical limb ischemia: The SCELTA trial. Circ J 2018; 82: 1688–1698. (Regenerative Medicine)

 (7) Sezai A, Obata K, Abe K, Kanno S, Sekino H. Cross-over trial of febuxostat and topiroxostat for hyperuricemia with cardiovascular disease (TROFEO trial). Circ J 2017; 81: 1707–1712. (Preventive Medicine)

11. (6) Abe Y, Akamatsu K, Ito K, Matsumura Y, Shimeno K, Naruko T, et al. Prevalence and prognostic significance of functional mitral and tricuspid regurgitation despite preserved left ventricular ejection fraction in atrial fibrillation patients. Circ J 2018; 82: 1451–1458. (Valvular Heart Disease)

 (6) Hayashida R, Kondo K, Morita S, Unno K, Shintani S, Shimizu Y, et al. Diallyl trisulfide augments ischemia-induced angiogenesis via an endothelial nitric oxide synthase-dependent mechanism. Circ J 2017; 81: 870–878. (Vascular Biology and Vascular Medicine)

 (6) Nagar SP, Rane PP, Fox KM, Meyers J, Davis K, Beaubrun A, et al. Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. Circ J 2018; 82: 1008–1016. (Epidemiology)

 (6) Saji M, Higuchi R, Tobaru T, Iguchi N, Takanashi S, Takayama M, et al. Impact of frailty markers for unplanned hospital readmission following transcatheter aortic valve implantation. Circ J 2018; 82: 2191–2198. (Valvular Heart Disease)

 (6) Wei XB, Chen F, Huang JL, He PC, Wei YX, Tan N, et al. Novel risk biomarker for infective endocarditis patients with normal left ventricular ejection fraction: Monocyte to high-density lipoprotein cholesterol ratio. Circ J 2018; 82: 283–288. (Valvular Heart Disease)

 (6) Matsuo H, Dohi K, Machida H, Takeuchi H, Aoki T, Nishimura H, et al. Echocardiographic assessment of cardiac structural and functional abnormalities in patients with end-stage renal disease receiving chronic hemodialysis. Circ J 2018; 82: 586–595. (Valvular Heart Disease)

 (6) Kim BJ, Seo DC, Kim BS, Kang JH. Relationship between cotinine-verified smoking status and incidence of hypertension in 74,743 Korean adults. Circ J 2018; 82: 1659–1665. (Hypertension and Circulatory Control)

 (6) Ikeda K, Mizoro Y, Ameku T, Nomiya Y, Mae SI, Matsui S, et al. Transcriptional analysis of intravenous immunoglobulin resistance in Kawasaki disease using an induced pluripotent stem cell disease model. Circ J 2017; 81: 110–118. (Vascular Biology and Vascular Medicine)

19. (5) Nagao K, Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, et al; CURRENT AS registry investigators. Acute heart failure in patients with severe aortic stenosis: Insights from the CURRENT AS registry. Circ J 2018; 82: 874–885. (Valvular Heart Disease)

 (5) Tanaka N, Irino Y, Shinohara M, Tsuda S, Mori T, Nagao M, et al. Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties. Circ J 2018; 82: 596–601. (Vascular Biology and Vascular Medicine)

 (5) Tamaki S, Sato Y, Yamada T, Morita T, Furukawa Y, Iwasaki Y, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction: Prospective randomized controlled study. Circ J 2017; 81: 740–747. (Renal Disease)

 (5) Kario K, Bhatt DL, Brar S, Bakris GL. Differences in dynamic diurnal blood pressure variability between Japanese and American treatment-resistant hypertensive populations. Circ J 2017; 81: 1337–1345. (Hypertension and Circulatory Control)

 (5) Soltani Hekmat A, Javanmardi K, Kouhpayeh A, Baharamali E, Farjam M. Differences in cardiovascular responses to alamandine in two-kidney, one clip hypertensive and normotensive rats. Circ J 2017; 81: 405–412. (Vascular Biology and Vascular Medicine)

 (5) Cheng HP, Gong D, Zhao ZW, He PP, Yu XH, Ye Q, et al. MicroRNA-182 promotes lipoprotein lipase expression and atherogenesisby targeting histone deacetylase 9 in apolipoprotein E-knockout mice. Circ J 2018; 82: 28–38. (Aortic Disease)

 (5) Tajima Y, Goto H, Ohara M, Hashimoto M, Akamatsu D, Shimizu T, et al. Oral steroid use and abdominal aortic aneurysm expansion: Positive association. Circ J 2017; 81: 1774–1782. (Aortic Disease)

The Editorial Team looks forward to receiving manuscripts with high scientific impact from all over the world.

  • Toshihisa Anzai, MD, PhD
  • Editor-in-Chief
  • Circulation Journal

 
© 2020 THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top